Académique Documents
Professionnel Documents
Culture Documents
RESEARCHHUMANCLINICAL STUDIES
chordoma recurrence.
METHODS: Retrospective review of clival chordomas treated at our center from 1993 to
2013.
RESULTS: Fifty patients (56% male) with median age of 59 years (range, 8-76) were newly
diagnosed with clival chordoma of mean diameter 3.3 cm (range, 1.5-6.7). Symptoms included
headaches (38%), diplopia (36%), and dysphagia (14%). Procedures included transsphenoidal
(n = 34), transoral (n = 4), craniotomy (n = 5), and staged approaches (n = 7). Gross total resection
(GTR) rate was 52%, with 83% mean volumetric reduction, values that improved over time. While
the lower third of the clivus was the least likely superoinferior zone to contain tumor (upper
third = 72%/middle third = 82%/lower third = 42%), it most frequently contained residual tumor
(upper third = 33%/middle third = 38%/lower third = 63%; P , .05). Symptom improvement
rates were 61% (diplopia) and 53% (headache). Postoperative radiation included proton beam
(n = 19), cyberknife (n = 7), intensity-modulated radiation therapy (n = 6), external beam (n = 10),
and none (n = 4). At last follow-up of 47 patients, 23 (49%) remain disease-free or have stable
residual tumor. Lower third of clivus progressed most after GTR (upper/mid/lower third = 32%/
41%/75%). In a multivariate Cox proportional hazards model, male gender (hazard ratio [HR] =
1.2/P = .03), subtotal resection (HR = 5.0/P = .02), and the preoperative presence of tumor in the
middle third (HR = 1.2/P = .02) and lower third (HR = 1.8/P = .02) of the clivus increased further
growth or regrowth, while radiation modality did not.
CONCLUSION: Our findings underscore long-standing support for GTR as reducing chordoma recurrence. The lower third of the clivus frequently harbored residual or recurrent tumor,
despite staged approaches providing mediolateral (transcranial 1 endonasal) or superoinferior (endonasal 1 transoral) breadth. There was no benefit of proton-based over photonbased radiation, contradicting conventional presumptions.
DOI: 10.1227/NEU.0000000000000611
NEUROSURGERY
www.neurosurgery-online.com
JAHANGIRI ET AL
METHODS
Study Design and Population
We retrospectively reviewed University of California, San Francisco
(UCSF) department of neurological surgerys database and identified 50
examples of patients undergoing initial resection of clival chordoma
between 1993 and 2013. The UCSF Committee on Human Research
approved this study in advance.
Parameters Assessed
Original pathology and operative reports were reviewed to confirm the
diagnosis of chordoma and the surgical approach used. The age at diagnosis
was documented as the patients age at the time of the initial operation. All
parameters were reviewed separately by 2 members of the study team.
Imaging
Preoperative and postoperative MRIs were reviewed by the study team
to assess (1) tumor size, which was recorded at its longest in all 3
dimensions (anteroposterior, left to right, and superoinferior) along with
the average of the 3 dimensions; (2) tumor volume, measured using
AWServer software (GE Healthcare; San Francisco, California) to outline
areas of the tumor on sequential sagittal images with each volume
calculation repeated by 2 members of the study team to confirm
concordance; (3) superoinferior zones of involvement; and (4) the
presence of tumor medial/lateral to the carotid artery. Superoinferior
zones of involvement were classified as (1) upper third of the clivus
from dorsum sellae and posterior clinoids to the plane of Dorello canal,
including the paraclinoidal and intracavernous segments of the carotid
artery, the interpeduncular cistern, the third cranial nerve, the basilar
apex, the superior cerebellar artery, and posterior cerebral artery; (2)
middle third of clivusfrom the petrous apex at Dorello canal to the
pars nervosa of the jugular foramen, including the paraclival carotid
artery, the sixth cranial nerve, the basilar trunk, the prepontine cistern,
and Meckel cave out laterally; and (3) lower third of clivusfrom
the pars nervosa to the foramen magnum, including down to the
parapharyngeal carotid segment, the hypoglossal canal, vertebral
arteries, and premedullary cistern. Postoperative MRIs were retrospectively reviewed by the study team until the last known MRI or the first
Cadaveric Analysis
Two human postmortem specimens were used to illustrate the
anatomic location of the residual/recurrent chordomas in our series.
The specimens were prepared for surgical simulation as previously
described by our group.11 An extended endoscopic endonasal approach
to the skull base and a transcranial far lateral approach were performed
and recorded.
Statistical Analysis
Kaplan-Meier analysis was used to assess and compare actuarial
radiographic recurrence rates in the group as a whole and in the various
patient subcategories, with time until radiographic recurrence or time
until last MRI showing no radiographic recurrence recorded for each
patient. Analysis of variance was used for parametric comparisons of more
than 2 variables when the dependent variable was continuous while a x2
test was used to compare more than 2 proportions. The Student t test
was used to perform parametric comparison between 2 variables. The
Fisher exact test was used to compare 2 proportions. P values are 2-tailed
and P , .05 was considered statistically significant.
RESULTS
Patient Population
Fifty patients (56% male) with a median age of 59 years (range,
8-76) were newly diagnosed with clival chordoma with mean
diameter 3.3 cm (range = 1.5-6.7). Presenting symptoms included
headaches (38%), diplopia (36%), and dysphagia (14%).
Preoperative Tumor Characteristics
Of the 39 tumors with digitized MRIs that could undergo
volumetric analysis, mean preoperative tumor volume was 18.4
cm3. Review of images of all 50 cases revealed that 72% occupied
the upper third of the clivus, 82% occupied the mid third of the
clivus, and 42% occupied the lower third of the clivus (Figure
1A). A more detailed radiographic review of specific structures in
and around the upper, mid, and lower third of the clivus revealed
the prepontine cistern behind the mid third of the clivus to be the
most involved area, at 66% of the cases, followed by the dorsum
sellae and posterior clinoids in the upper third of the clivus, which
were involved in 60% of the cases (Figure 1B).
Surgical Procedures Performed as First Treatment
For 43 patients undergoing a single surgical procedure, the most
common approach was endonasal transsphenoidal, performed in
34 patients (79%) by using either a microscope (n = 15) or
endoscope (n = 19). Four tumors (9%) were accessed exclusively
through transoral approaches owing to significant involvement of
the lower third of the clivus. Five tumors (12%) were resected
exclusively through a craniotomy (far lateral/suboccipital n = 2,
frontotemporal/orbitozygomatic n = 2, and middle fossa trans- or
www.neurosurgery-online.com
FIGURE 1. Locations of clival chordomas and representative MRIs. A, percentage of cases located in the upper, middle, and lower third of the clivus. Tumors were less
frequently located in the lower third of the clivus than in other locations (P , .05). B, percentage of cases located in the following specific structures found within or adjacent to
(lateral or posterior to) each third of the clivus: Upper third(1) dorsum sellae and posterior clinoids; (2) interpeduncular cistern; (3) basilar apex; (4) paraclinoidal/
intracavernous carotid; (5) cranial nerve III; (6) Dorello canal; and (7) posterior cerebral arteries. Middle third(1) prepontine cistern; (2) basilar trunk; (3) petrous apex; (4)
Dorello canal; (5) cranial nerve VI; (6) Meckel cave; (7) jugular foramen; and (8) paraclival carotid. Lower third(1) premedullary cistern; (2) foramen magnum; (3)
parapharyngeal carotid; (4) hypoglossal canal; and (5) vertebral artery. When separating clival and paraclival structures into those that were medial (1-3 in the upper third; 1-2
and 4 in the mid third; and 1-3 in the lower third) vs lateral (4-7 in the upper third; 3 and 5-8 in the mid third; and 4-5 in the lower third), medial structures were more likely
to contain tumor (P , .05). C, sagittal and coronal illustrations of the upper, mid, and lower thirds of the clivus with key locations in each third illustrated with the same
numbering system used in B with circles in each zone the size of which correspond to the frequency with which tumor occurred in that location. D, representative images of cases
treated and approaches used. First row shows 57-year-old man with diplopia and tumor in all 3 thirds of the clivus, specifically Dorello canal, cavernous carotid arteries, petrous
apices, cranial nerve VI, basilar trunk, prepontine cistern, and hypoglossal canal. Patient underwent endoscopic endonasal surgery with GTR followed by proton beam
radiation. Recurrence of tumor in the right hypoglossal canal 2 years later was treated with reoperation and external beam radiation. Second row shows 52-year-old woman
with shoulder and neck spasms and tumor in the lower third of the clivus, specifically in the hypoglossal canal, vertebral artery, premedullary cistern, and extending out the
foramen magnum. A transoral approach with tumor resection and odontoidectomy was performed. There was trace residual tumor encasing the pharyngeal carotid arteries
which the patient elected to observe and it has not progressed to date. Third row shows a 22-year-old man with shoulder and neck pain and tumor in the lower third of the clivus,
particularly the jugular foramen, prepontine cistern, and extending out beyond the foramen magnum. A combined transsphenoidal and transoral approach was performed,
followed by a retrosigmoid craniotomy. Resection was subtotal, followed by IMRT, with recurrence at 18 months. GTR, gross total resection; IMRT, intensity-modulated
radiation therapy.
NEUROSURGERY
JAHANGIRI ET AL
90% tumor removal, higher than achieved after the first stage
alone (P , .05) (Figure 2C).
Sites of Residual Tumor
Although the lower third of the clivus was the least likely
superoinferior clival zone to contain tumor (upper third = 72%,
middle third = 82%, lower third = 42%; Figure 1A-D), the rate
with which residual tumor occurred was highest in the lower
third of the clivus (upper third = 33%, middle third = 38%, lower
third = 63%; P , .05) (Figure 3A). More medial structures were
more likely to contain tumor than more lateral structures in and
around the clivus (P , .05; Figure 1B-C), consistent with the
medial origin of chordoma. Twenty-two chordomas extended
lateral to the carotid artery (44%), of which 9 (41%) received
GTR, comparable to the overall GTR rate of 52% (P . .05). Eight
of 24 residual chordomas (33%) occurred lateral to the carotid
artery, with 5 of these residual chordomas occurring exclusively
www.neurosurgery-online.com
NEUROSURGERY
Older age
Male sex
Approach
STR relative to GTR
Radiation modality
Size (cm diameter)
Upper third clivus
Mid third clivus
Lower third clivus
Lateral to carotid
Hazard Ratio
1.1
1.2
1.1
5.0
0.7
1.9
0.7
1.2
1.8
2.0
.06
.03
.7
.02
.4
.2
.7
.02
.02
.5
DISCUSSION
In this series of clival chordomas, we were able to support the
importance of achieving GTR in reducing recurrence, while
stressing other risk factors for recurrence including male sex and
tumor in the middle and lower third of the clivus as other risk
factors for recurrence. The importance of GTR in reducing
recurrence is consistent with previous studies, including studies
describing exclusive utilization of the endoscopic endonasal5,12,13
or transcranial12-14 approaches. Although a cancer registry found
age and tumor size to influence overall survival of chordoma
patients,15 these variables did not influence recurrence in our
single-institution study.
JAHANGIRI ET AL
CONCLUSION
Our findings underscore long-standing support for GTR as
reducing chordoma recurrence. We also found tumor in the mid or
lower third of the clivus to increase the risk of recurrence, with the
latter location a particularly frequent site of residual tumor and
recurrence after GTR, despite incorporating staged approaches
providing medio lateral (transcranial 1 endonasal) or superoinferior (endonasal 1 transoral) breadth. Our findings also
suggest no benefit of proton-based over photon-based radiation,
contradicting conventional presumptions and underscoring the
need for randomized trials addressing radiation modality.
Disclosure
Dr Ames is a consultant for DePuy, Stryker, and Medtronic. He has received
royalties from Aesculap and Biomet Spine. He owns stock and stock options in
Doctors Research Group, and Baxano Surgery, and he owns a patent with Fish and
Richardson, P.C. Dr Chou is a consultant for Globus, Medtronic, and Orthofix.
The other authors have no personal, financial, or institutional interest in any of the
drugs, materials, or devices described in this article.
REFERENCES
1. Eriksson B, Gunterberg B, Kindblom LG. Chordoma. A clinicopathologic and
prognostic study of a Swedish national series. Acta Orthop Scand. 1981;52(1):
49-58.
2. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma:
incidence and survival patterns in the United States, 1973-1995. Cancer Causes
Control. 2001;12(1):1-11.
3. Sen C, Triana AI, Berglind N, Godbold J, Shrivastava RK. Clival chordomas:
clinical management, results, and complications in 71 patients. J Neurosurg. 2010;
113(5):1059-1071.
4. Fernandez-Miranda JC, Gardner PA, Snyderman CH, et al. Clival chordomas:
a pathological, surgical, and radiotherapeutic review. Head Neck. 2014;36(6):
892-906.
5. Koutourousiou M, Gardner PA, Tormenti MJ, et al. Endoscopic endonasal
approach for resection of cranial base chordomas: outcomes and learning curve.
Neurosurgery. 2012;71(3):614-624; discussion 624-625.
6. Singh H, Harrop J, Schiffmacher P, Rosen M, Evans J. Ventral surgical
approaches to craniovertebral junction chordomas. Neurosurgery. 2010;66
(3 suppl):96-103.
7. Dehdashti AR, Karabatsou K, Ganna A, Witterick I, Gentili F. Expanded
endoscopic endonasal approach for treatment of clival chordomas: early results
in 12 patients. Neurosurgery. 2008;63(2):299-307; discussion 307-309.
www.neurosurgery-online.com
8. Jahangiri A, Jian B, Miller L, El-Sayed IH, Aghi MK. Skull base chordomas:
clinical features, prognostic factors, and therapeutics. Neurosurg Clin N Am. 2013;
24(1):79-88.
9. Yasuda M, Bresson D, Chibbaro S, et al. Chordomas of the skull base and cervical
spine: clinical outcomes associated with a multimodal surgical resection combined
with proton-beam radiation in 40 patients. Neurosurg Rev. 2012;35(2):171-182;
discussion 182-183.
10. Fuji H, Nakasu Y, Ishida Y, et al. Feasibility of proton beam therapy for
chordoma and chondrosarcoma of the skull base. Skull Base. 2011;21(3):201206.
11. Benet A, Rincon-Torroella J, Lawton MT, Gonzlez Snchez JJ. Novel embalming
solution for neurosurgical simulation in cadavers. J Neurosurg. 2014;120(5):
1229-1237.
12. Colli B, Al-Mefty O. Chordomas of the craniocervical junction: follow-up review
and prognostic factors. J Neurosurg. 2001;95(6):933-943.
13. Sen CN, Sekhar LN, Schramm VL, Janecka IP. Chordoma and chondrosarcoma
of the cranial base: an 8-year experience. Neurosurgery. 1989;25(6):931-940;
discussion 940-941.
14. Gay E, Sekhar LN, Rubinstein E, et al. Chordomas and chondrosarcomas of the
cranial base: results and follow-up of 60 patients. Neurosurgery. 1995;36(5):887896; discussion 896-897.
15. Jones PS, Aghi MK, Muzikansky A, Shih HA, Barker FG II, Curry WT Jr.
Outcomes and patterns of care in adult skull base chordomas from the SEER
database. J Clin Neurosci. 2014;21(9):1497-1502.
16. Tzortzidis F, Elahi F, Wright D, Natarajan SK, Sekhar LN. Patient outcome at
long-term follow-up after aggressive microsurgical resection of cranial base
chordomas. Neurosurgery. 2006;59(2):230-237; discussion 230-237.
17. El-Sayed IH, Wu JC, Ames CP, Balamurali G, Mummaneni PV. Combined
transnasal and transoral endoscopic approaches to the craniovertebral junction.
J Craniovertebr Junction Spine. 2010;1(1):44-48.
18. Burke K, Benet A, Aghi MK, El-Sayed I. Impact of platybasia and anatomic
variance on surgical approaches to the craniovertebral junction. Laryngoscope.
2014;124(8):1760-1766.
19. Austin-Seymour M, Munzenrider J, Goitein M, et al. Fractionated proton
radiation therapy of chordoma and low-grade chondrosarcoma of the base of the
skull. J Neurosurg. 1989;70(1):13-17.
20. Di Maio S, Temkin N, Ramanathan D, Sekhar LN. Current comprehensive
management of cranial base chordomas: 10-year meta-analysis of observational
studies. J Neurosurg. 2011;115(6):1094-1105.
21. Torres MA, Chang EL, Mahajan A, et al. Optimal treatment planning for skull
base chordoma: photons, protons, or a combination of both? Int J Radiat Oncol
Biol Phys. 2009;74(4):1033-1039.
22. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base.
Strahlenther Onkol. 1999;175(suppl 2):57-63.
23. Staab A, Rutz HP, Ares C, et al. Spot-scanning-based proton therapy for
extracranial chordoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e489-e496.
24. Kano H, Iqbal FO, Sheehan J, et al. Stereotactic radiosurgery for chordoma:
a report from the North American Gamma Knife Consortium. Neurosurgery. 2011;
68(2):379-389.
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions of this
article on the journals Web site (www.neurosurgery-online.com).
COMMENTS
rom various publications, and from a systematic analysis of the publications, we know some facts about the treatment of chordomas, and
their recurrence (or progression). The 1 factor that has been shown to be
important in regard to recurrence is total tumor resection. So, any surgical
approach(es) which can improve this in a particular patient is important.1
In our hands, the now well-established skull base approaches work very
well to achieve total resection, either in one, or a two staged operations.
At present, in primary (previously unoperated) cases, we are able to
achieve this in better than 95% of cases, but the rate of total removal
NEUROSURGERY
JAHANGIRI ET AL
his article presents the experience from the UCSF Medical center in the
treatment of chordomas. It adds no novel information to our current
knowledge, but still it illustrates several aspects of the management of skull
base chordomas that are worth emphasizing. First, the authors provide
further evidence of the critical importance of achieving gross total resection
by showing a faster and significantly increased risk of recurrence/regrowth
after subtotal resection. It is our current strategy at UPMC to always perform
a fine-cut T1 and T2 MRI on postoperative day 1 or 2 to identify any
residual tumor that could be amenable for further resection. Our current
resection rates for original clival chordomas is greater than 90%, which takes
us to the second important aspect nicely illustrated in this report: the
introduction of the endoscopic endonasal approach and the learning curve
for the surgical treatment of chordomas.
Their reported gross total resection rate of 52% is well below current
standards, but when looking carefully at their data, in particular, Figure
2B, it is clear that, since the introduction of endoscopic endonasal
surgery, their resection rates have progressively improved from 64% to
80%, which represents a remarkable improvement compared with the
initial rate of 31%.1 These data clearly exemplify the dramatic impact
that the introduction of endoscopic endonasal surgery has had in the
management of skull base chordomas. In our current practice, the
endoscopic endonasal approach represents the single most important
approach for clival chordomas, while transcranial microsurgical approaches remain as additional options for large and/or recurrent tumors
that cannot be fully resected via the endonasal route.
Yet, another critical point of this article is the excessively high rate of
residual tumor at the lower clival area (63%), something that was also
found on our clinical series where we observed an initial (2003-2007)
residual tumor rate at the lower clivus of 75% that was improved to 38%
for the period 2008 to 2011. Tumors extending to the jugular foramen,
hypoglossal canal, occipital condyle, and occipitocervical junction are
challenging and may cause significant morbidity. Not only the learning
curve of the surgical technique, but also a better understanding of the
complex surgical anatomy of the lower clivus is paramount to increase
resection rates and minimize surgical morbidity.2
Finally, the authors show that proton- and photon-based radiotherapy
yielded similar results. This study is obviously neither designed nor valid
to address this important debate, but it is just another one that raises the
urge to perform multicentric randomized trials evaluating proton- vs
photon-based radiotherapy for patients with chordoma.
Juan C. Fernandez-Miranda
Pittsburgh, Pennsylvania
CME QUESTIONS:
1. What is the cell of origin of chordomas?
A. Physaliferous cells
B. Notochord remnants
C. Arachnoid cap cells
D. Rathkes pouch epithelium
2. A 35-year-old male presents with headaches, diplopia and right
abducens nerve palsy; his MRI is shown below. What is the most
likely diagnosis?
A. Chondrosarcoma
B. Chordoma
C. Plasmacytoma
D. Pituitary macroadenoma
E. Clival meningioma
3. What theoretical advantage does proton beam therapy offer for the
treatment of chordomas?
www.neurosurgery-online.com